Thus, it will be of tremendous interest to determine whether the accumulation of DNA damage within SKP1-deficient cancer cells or appropriate mouse models are associated with increased sensitivity towards genotoxic agents or whether these cells/models can be selectively targeted with immune checkpoint inhibitors or precision-based therapeutic strategies. This evidence concerns the gene SKP1 and cancer.